[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Transcend Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100657247","phase-3-an-evaluation-of-the-safety-and-efficacy-of-tsnd-201-for-the-treatment-of-ptsd-100657247",false,"NCT07836647","An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD","EMPOWER-2","Inclusion Criteria:\n\n* Meets DSM-5 criteria for current PTSD diagnosis, with a symptom duration of at least 6 months.\n* Tried at least one pharmacological treatment for PTSD or trauma-focused psychotherapy.\n* Proficient in communication (verbal and reading) to complete interviews and written questionnaires.\n* Free from any other clinically significant illness or disease.\n\nExclusion Criteria:\n\n* Primary diagnosis of any other DSM-5 disorder.\n* Body mass index (BMI) \\\u003C18kg\u002Fm2 or ≥40 kg\u002Fm2.\n* Unable to refrain from nicotine use for at least 8 hours.\n* Use of prohibited concomitant medications or therapies.\n* Current or previous history of clinically significant cardiovascular (including current uncontrolled hypertension) \u002F cerebrovascular conditions.","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.",[27],"Post Traumatic Stress Disorder",[29,15,30,31,32],"PTSD","Transcend Therapeutics","TSND-201","Neuroplastogen","RECRUITING","2026-09-17",{"date":36,"type":37},"2026-09-23","ACTUAL",{"date":39,"type":21},"2026-09",{"date":41,"type":21},"2028-02",{"name":30,"class":43},"INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":14,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100628058","phase-3-an-evaluation-of-the-safety-and-efficacy-of-tsnd-201-for-the-treatment-of-ptsd-empower-1-100628058","NCT07456696","An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)","EMPOWER-1","Inclusion Criteria:\n\n* Meets the DSM-5 criteria for current PTSD diagnosis, with a symptom duration of at least 6 months.\n* Tried at least one pharmacological treatment for PTSD or trauma-focused psychotherapy.\n* Proficient in communication (verbal and reading) to complete interviews and written questionnaires.\n* Free from any other clinically significant illness or disease.\n\nExclusion Criteria:\n\n* Primary diagnosis of any other DSM-5 disorder.\n* Body mass index (BMI) \\\u003C18 kg\u002Fm2 or ≥40 kg\u002Fm2.\n* Unable to refrain from nicotine use for at least 8 hours.\n* Use of prohibited concomitant medications or therapies.\n* Current or previous history of clinically significant cardiovascular (including current uncontrolled hypertension) \u002F cerebrovascular conditions.",{"count":20,"type":21},[24],"This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD.\n\nEligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.",[27],[29,49,30,31,32],"2026-09-14",{"date":34,"type":37},{"date":59,"type":37},"2026-04-02",{"date":61,"type":21},"2027-12",{"name":30,"class":43},37,""]